Diverse and ambitious projects
NETRF is pursuing multiple paths to discover improved treatments for NETs. We have an evolving portfolio of diverse basic, translational, and clinical projects, covering a plethora of challenging but crucial research areas within NETs.
We focus on ideas that will give us tangible results, and have translational potential, while also investing in areas that have direct impact on patients’ lives (theranostics – PRRT) and/or have been successfully applied in other types of cancers (CAR T-cell therapy).
We continue to build on past successes in areas such as genetics/epigenetics (DAXX/ATRX), etc., and work on creating tools for the entire community (mouse models, patient-derived xenografts, organoids, cell lines, etc.).
We have a long-standing interest in understanding the molecular underpinnings of NETs, and the mechanisms that drive tumor initiation and progression. We fund proposals that suggest innovative ways to study NETs in the absence of conventional models, as well as proposals to create new or optimize existing experimental models. We have the ability to fund small clinical and adaptive studies, studies of therapeutic sequencing, as well as correlative studies that may build upon existing clinical trials.
Our portfolio includes research aimed at: cracking the genetic and epigenetic code; deciphering the molecular underpinnings of NETs to discover vulnerabilities that can be exploited to interrupt NET development/progression; understanding the immune microenvironment and creating technologies that will trigger an immune response; developing reliable disease models for laboratory experiments to discover new drug targets, and determine the safety and efficacy of potential treatments, before testing in humans; advancing the effectiveness of current PRRT treatments; identifying new drug targets; discovering diagnostic/prognostic markers that can guide treatment planning and sequencing decisions, etc.
While we have traditionally funded research in pancreatic and gastrointestinal NETs, we are excited to expand our portfolio to include lung carcinoids.
The latest in NET News
Immunotherapy has been called one of the most significant advances in cancer in decades. While
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD,
https://www.youtube.com/watch?v=k1906SABias The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing